Peer reviewed papers published in close succession in PNAS, Nature Communications Chemistry and Nature Communications Biology
Collectively these papers describe how chemistry can be made programmable through Chemputation, how the scientific literature can be verified and executed via physical AI systems and how it could discover new drugs for cancer research
Lee Cronin, CEO and founder of Chemify, the deep-tech pioneer of Chemputation a technological breakthrough that integrates AI- and ML-driven molecular discovery and automated, robotic synthesis has published three peer-reviewed research papers in close succession, constituting a technological tour de force that validates Chemputation as a new paradigm for how small molecule-drugs and materials are discovered, designed and manufactured.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260409370277/en/
Lee Cronin, CEO and founder of Chemify, the deep-tech pioneer of Chemputation a technological breakthrough that integrates AI- and ML-driven molecular discovery and automated, robotic synthesis has published three peer-reviewed research papers in close succession, constituting a technological tour de force that validates Chemputation as a new paradigm for how small molecule-drugs and materials are discovered, designed and manufactured. The three publications in PNAS, Nature Communications Chemistry and Nature Communications Biology describe how the Chemputation AI platform can understand and execute instructions to make new molecules from scientific literature, produce them iteratively and how this could be applied to cancer research.
The three publications in PNAS, Nature Communications Chemistry and Nature Communications Biology describe how the Chemputation AI platform can understand and execute instructions to make new molecules from scientific literature, produce them iteratively and how this could be applied to cancer research. Together, these three papers demonstrate the potential of Chemputation to digitize chemistry and become the foundation for the autonomous discovery, manufacturing and generation of high-value molecules at scale.
"Chemputation has been established as a new paradigm, critical for the future of chemical discovery and manufacture, and I'm proud that Chemify is building on these discoveries delivering real molecules using Chemputation AI to our partners," said Lee Cronin, CEO and founder of Chemify. "Chemputation shifts chemistry from an artisanal practice to an executable, verifiable and shareable technology and opens the door to a future where drugs, materials and entirely new and makeable molecules can be designed, compiled and manufactured as easily as software."
The three papers were all published within the last two weeks by Lee Cronin and multidisciplinary co-authors from the University of Glasgow, where Cronin has a lab.
- The Proceedings of the National Academy of Sciences publication from April 7, "Chemputer and chemputation-A universal chemical compound Synthesis Machine," discusses a new proof that chemical molecules can be made using the chemputation process, opening the way to use one simple programming language to make molecules.
- The Nature Communications Chemistry publication from April 3, "Verification and execution of the scientific literature via chemputation augmented by large language models," describes how a system of agents is used to both read and correct the chemical literature so that the procedures can be safely used by robots capable of Chemputation to autonomously make the molecules and verify the process.
- The Nature Communications Biology publication from March 27, "Chemical programming of kinase inhibitors in a modular chemputer-based system," shows how the Chemputation system can be used to iterate on new potential cancer treatments based on targeting a model of KRAS-mutant colorectal cancer in a practical example of how Chemputation is being applied to address challenges in preclinical drug discovery.
Chemify was founded in 2022 as a spin-out from the University of Glasgow, and closed a $50 million Series B financing co-led by Wing Venture Capital and Insight Partners in October of 2025. Chemify opened its first Chemifarm in June of 2025 to revolutionize molecular design and manufacturing, and has a variety of active small molecule research collaborations with multiple biotech, pharmaceutical and institutional partners.
About Chemputation
Chemify's Chemputation technology merges AI/ML-based design with a universal programming language for chemistry and advanced software and robotics, empowering partners to move seamlessly from novel concept to makeable compound. The closed-loop workflow accelerates iteration and enhances design confidence to achieve high-quality hits and leads with exceptional speed and precision.
About Chemify
Chemify is reimagining the discovery and synthesis of novel molecules for medicines and advanced materials by turning digital code into physical compounds through Chemputation-its fusion of robotics and AI. Headquartered in Glasgow, Scotland, the company was founded by Lee Cronin to digitalize chemistry at global scale for the benefit of humanity. Learn more at Chemify.io and follow @ChemifyX on X/Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260409370277/en/
Contacts:
Media Contact
Tim Ingersoll
Linnden Communications
Tim@linndencom.com
